Cover Image
市場調查報告書

小細胞肺癌症治療藥的全球市場:2015年∼2019年

Global Small Cell Lung Cancer Therapeutics Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 326315
出版日期 內容資訊 英文 102 Pages
訂單完成後即時交付
價格
Back to Top
小細胞肺癌症治療藥的全球市場:2015年∼2019年 Global Small Cell Lung Cancer Therapeutics Market 2015-2019
出版日期: 2015年03月18日 內容資訊: 英文 102 Pages
簡介

肺癌症,可分為非小細胞肺癌和小細胞肺癌2種。小細胞肺癌症,佔肺癌和確診的全病例約10∼15%。全球小細胞肺癌症治療藥市場,2014年∼2019年預計以3.6%的年複合成長率成長。

本報告提供全球小細胞肺癌症治療藥市場相關調查分析、市場規模與成長率、市場趨勢、市場的推動要素與課題、市場機會驗證、主要供應商等相關的系統性資訊。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 疾病概要

  • 關於疾病
  • 分類
  • 診斷
  • 發病率和患者數
  • 分期
  • 管理
  • 經濟負擔

第6章 簡介

第7章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 主要預測
  • 波特的五力分析

第8章 開發平台分析

  • 開發平台候補相關主要資訊
  • 正在開發的主要產品的時間軸

第9章 市場區隔:各治療分類

  • 烷化劑
  • 代謝拮抗劑
  • 微管抑制劑
  • 細胞傷害性抗生素
  • 異構轉化梅抑制劑
  • 其他

第10章 市場區隔:各給藥途徑

  • 口服
  • 非口服

第11章 市場區隔:各劑型

  • 固體
  • 液體

第12章 地區區分

  • 南北美洲的小細胞肺癌症市場
    • 市場規模與預測
  • 歐洲、中東、非洲地區的小細胞肺癌症市場
    • 市場規模與預測
  • 亞太地區的小細胞肺癌症市場
    • 市場規模與預測

第13章 購買標準

第14章 推動市場成長要素

第15章 成長推動因素與其影響

第16章 市場課題

第17章 成長推動因素與課題的影響

第18章 市場趨勢

第19章 趨勢與其影響

第20章 業者情勢

  • 競爭模式
  • 市場佔有率分析
  • 其他卓越供應商

第21章 主要供應商分析

  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Menarini
  • Sanofi
  • ZIOPHARM Oncology

第22章 相關報告

圖表

目錄
Product Code: IRTNTR5579

About Small Cell Lung Cancer

Cancer occurs when, after cell transformation, normal cells grow and multiply without control. Lung cancer is a common cause of mortality and morbidity in developed and developing countries. Smoking is considered to be the major cause of small cell lung cancer, though it also occurs in non-smokers. Lung cancer can be categorized into two types: non-small cell lung cancer and small cell lung cancer. Small cell lung cancer constitutes roughly 10-15 percent of all diagnosed cases of lung cancer. Small cell lung cancer is categorized into two types: small cell carcinoma and combined small cell carcinoma. It can be further classified into two stages: limited-stage small cell lung cancer and extensive-stage small cell lung cancer. Small cell lung cancer is caused by smoking tobacco, or second hand smoking, or on exposure to asbestos, chromium, arsenic, nickel, soot, or radon. The common symptoms associated with lung cancer are chest pain, incurable cough, blood in sputum, fatigue, loss of appetite, unintentional weight loss, shortness of breath, and wheezing. Small cell lung cancer has a poor prognosis and gets diagnosed only at the late stage of disease progression, and hence, has a high mortality rate. There are no therapies available to cure small cell lung cancer in the market.

TechNavio's analysts forecast the Global Small Cell Lung Cancer Therapeutics market to grow at a CAGR of 3.60 percent over the period 2014-2019.

Covered in this Report

TechNavio's report, Global Small Cell Lung Cancer Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Small Cell Lung Cancer Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Menarini
  • Sanofi
  • ZIOPHARM Oncology

Other Prominent Vendors

  • Alchemia
  • Amgen
  • Apotex
  • BioMarin Pharmaceutical
  • CellAct Pharma
  • Cerulean Pharma
  • Cipla
  • Cornerstone Pharmaceuticals
  • Curis
  • CytRx
  • Eli Lilly
  • Exelixis
  • Fresenius Kabi
  • Genentech
  • Hikma Pharmaceuticals
  • Hospira
  • Intas Pharmaceuticals
  • Karyopharm Therapeutics
  • Kyowa Hakko Kirin
  • Ligand Pharmaceuticals
  • Lundbeck
  • MabVax Therapeutics Holdings
  • Medac Pharma
  • MEI Pharma
  • Merck
  • MolMed
  • Mologen
  • Mylan
  • Nektar Therapeutics
  • Neotropix
  • Novartis
  • Novogen
  • OncoMed Pharmaceuticals
  • Ono Pharmaceutical
  • PharmaMar
  • Polaris Group
  • Sagent Pharmaceuticals
  • Shanghai Jinhe Bio-Technology
  • Spectrum Pharmaceuticals
  • STADA Arzneimittel
  • Stem CentRx
  • Sun Pharmaceuticals Industries
  • Takeda Pharmaceutical
  • Teva Pharmaceutical
  • Zydus Cadila Healthcare

Market Driver

  • High Unmet Need
  • For a full, detailed list, view our report

Market Challenge

  • High Cost of Treatment
  • For a full, detailed list, view our report

Market Trend

  • Strategic Alliances
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Disease Overview

  • 05.1. Understanding the Disease
  • 05.2. Classification
    • 05.2.1. Small Cell Carcinoma
    • 05.2.2. Combined Small Cell Carcinoma
  • 05.3. Diagnosis
    • 05.3.1. Physical Examination
    • 05.3.2. Laboratory Tests
    • 05.3.3. Chest X-ray
    • 05.3.4. Sputum Cytology
    • 05.3.5. CT Scan
    • 05.3.6. Biopsy
    • 05.3.7. Light and Electron Microscopy
    • 05.3.8. Immunohistochemistry
  • 05.4. Rate of Incidence and Prevalence
  • 05.5. Staging
  • 05.6. Management
  • 05.7. Economic Burden

06. Introduction

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. Top Predictions
  • 07.4. Five Forces Analysis

08. Pipeline Analysis

  • 08.1. Key Information on the Pipeline Candidates
    • 08.1.1. Palifosfamide (ZIO-201)
    • 08.1.2. Ipilimumab+Etoposide+Cisplatin/Carboplatin
    • 08.1.3. Ipilimumab
    • 08.1.4. Enoxaparin Sodium
    • 08.1.5. BAY1000394 (Roniciclib)
    • 08.1.6. Nivolumab (ONO-4538/ BMS-936558)
    • 08.1.7. BMS-986012
    • 08.1.8. LY2940680
    • 08.1.9. Sabarubicin (MEN 10755)
    • 08.1.10. CAP7.1
    • 08.1.11. SC16LD6.5
    • 08.1.12. BIW-8962
    • 08.1.13. AMG 479 (Ganitumab)
    • 08.1.14. LY2510924
    • 08.1.15. Trisenox
    • 08.1.16. MGN1703
    • 08.1.17. Tarextumab (OMP-59R5)
    • 08.1.18. BMN 673 (Talazoparib Tosylate)
    • 08.1.19. NGR-hTNF
    • 08.1.20. CPI-613
    • 08.1.21. Alisertib (MLN8237)
    • 08.1.22. Vismodegib (GDC-0449, Erivedge)
    • 08.1.23. Cabozantinib (XL184 or Cometriq)
    • 08.1.24. Selinexor (KPT-330)
    • 08.1.25. ADI-PEG 20 (Pegargiminase)
    • 08.1.26. Etirinotecan Pegol (NKTR-102)
    • 08.1.27. CRLX101 (IT-101 or Cyclodextrin-based Polymer-camptothecin IT-101)
    • 08.1.28. NTX-010
    • 08.1.29. Aldoxorubicin
    • 08.1.30. HA-Irinotecan
    • 08.1.31. Carfilzomib
    • 08.1.32. Small Cell Lung Cancer Vaccine
    • 08.1.33. GSK2879552
    • 08.1.34. NV-344 (ME-344)
    • 08.1.35. BMS-833923 (XL139)
    • 08.1.36. PM01183 (Lurbinectedin)
    • 08.1.37. LDE225 (Erismodegib or Sonidegib)
    • 08.1.38. Belinostat
  • 08.2. Timeline for Major Products under Development
    • 08.2.1. Palifosfamide (ZIO-201)
    • 08.2.2. Sabarubicin (MEN 10755)

09. Market Segmentation by Therapeutic Class of Drugs

  • 09.1. Alkylating Agents
  • 09.2. Antimetabolites
  • 09.3. Microtubule Inhibitors
  • 09.4. Cytotoxic Antibiotics
  • 09.5. Topoisomerase Inhibitors
  • 09.6. Others

10. Market Segmentation by Route of Administration

  • 10.1. Oral
  • 10.2. Parenteral

11. Market Segmentation by Dosage Form

  • 11.1. Solid
  • 11.2. Liquid

12. Geographical Segmentation

  • 12.1. Small Cell Lung Cancer Market in Americas
    • 12.1.1. Market Size and Forecast
  • 12.2. Small Cell Lung Cancer Market in EMEA Region
    • 12.2.1. Market Size and Forecast
  • 12.3. Small Cell Lung Cancer Market in APAC Region
    • 12.3.1. Market Size and Forecast

13. Buying Criteria

14. Market Growth Drivers

15. Drivers and their Impact

16. Market Challenges

17. Impact of Drivers and Challenges

18. Market Trends

19. Trends and their Impact

20. Vendor Landscape

  • 20.1. Competitive Scenario
    • 20.1.1. Key News
    • 20.1.2. Mergers and Acquisitions
  • 20.2. Market Share Analysis 2014
    • 20.2.1. Bristol-Myers Squibb
    • 20.2.2. GlaxoSmithKline
    • 20.2.3. Menarini
    • 20.2.4. Sanofi
    • 20.2.5. ZIOPHARM Oncology
  • 20.3. Other Prominent Vendors

21. Key Vendor Analysis

  • 21.1. Bristol-Myers Squibb
    • 21.1.1. Key Facts
    • 21.1.2. Business Overview
    • 21.1.3. Key Product Offerings
    • 21.1.4. Revenue by Geography
    • 21.1.5. Business Strategy
    • 21.1.6. Key Information
    • 21.1.7. SWOT Analysis
  • 21.2. GlaxoSmithKline
    • 21.2.1. Key Facts
    • 21.2.2. Business Overview
    • 21.2.3. Business Segmentation
    • 21.2.4. Business Segmentation by Revenue 2012 and 2013
    • 21.2.5. Sales by Geography
    • 21.2.6. Pipeline Products
    • 21.2.7. Business Strategy
    • 21.2.8. Key Information
    • 21.2.9. SWOT Analysis
  • 21.3. Menarini
    • 21.3.1. Key Facts
    • 21.3.2. Business Overview
    • 21.3.3. Key Pipeline Products
    • 21.3.4. Recent Developments
    • 21.3.5. SWOT Analysis
  • 21.4. Sanofi
    • 21.4.1. Key Facts
    • 21.4.2. Business Description
    • 21.4.3. Business Segmentation
    • 21.4.4. Revenue by Business Segmentation
    • 21.4.5. Revenue Comparison 2012 and 2013
    • 21.4.6. Sales by Geography
    • 21.4.7. Business Strategy
    • 21.4.8. Key Developments
    • 21.4.9. SWOT Analysis
  • 21.5. ZIOPHARM Oncology
    • 21.5.1. Key Facts
    • 21.5.2. Business Overview
    • 21.5.3. Recent Developments
    • 21.5.4. SWOT Analysis

22. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Classification of Lung Cancer
  • Exhibit 3: Techniques for Diagnosing Small Cell Lung Cancer
  • Exhibit 4: Incidence of Lung Cancer in WHO Regions
  • Exhibit 5: Staging of Small Cell Lung Cancer
  • Exhibit 6: Small Cell Lung Cancer by Stage
  • Exhibit 7: Five-year Survival Rate of Small Cell Lung Cancer Patients
  • Exhibit 8: Stepwise Diagrammatic Representation of Management of Small Cell Lung Cancer (According to ESMO Guidelines)
  • Exhibit 9: Global Small Cell Lung Cancer Therapeutics Market 2014-2019 (US$ million)
  • Exhibit 10: Top Predictions in Global Small Cell Lung Cancer Therapeutics Market
  • Exhibit 11: Pipeline Portfolio of Small Cell Lung Cancer Drugs
  • Exhibit 12: Timeline of Palifosfamide (ZIO-201)
  • Exhibit 13: Timeline of Sabarubicin (MEN 10755)
  • Exhibit 14: Global Small Cell Lung Cancer Therapeutics Market by Therapeutic Class of Drugs
  • Exhibit 15: Segmentation of Global Small Cell Lung Cancer Therapeutics Market by Route of Administration
  • Exhibit 16: Segmentation of Global Small Cell Lung Cancer Therapeutics Market by Route of Administration 2014
  • Exhibit 17: Segmentation of Global Small Cell Lung Cancer Therapeutics Market by Dosage Forms
  • Exhibit 18: Segmentation of Global Small Cell Lung Cancer Therapeutics Market by Dosage Forms 2014
  • Exhibit 19: Segmentation of Global Small Cell Lung Cancer Therapeutics Market by Geography 2014
  • Exhibit 20: Segmentation of Global Small Cell Lung Cancer Therapeutics Market by Geography 2019
  • Exhibit 21: Small Cell Lung Cancer Therapeutics Market in Americas 2014-2019 (US$ million)
  • Exhibit 22: Small Cell Lung Cancer Therapeutics Market in EMEA Region 2014-2019 (US$ million)
  • Exhibit 23: Small Cell Lung Cancer Therapeutics Market in APAC Region 2014-2019 (US$ million)
  • Exhibit 24: Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
  • Exhibit 25: Bristol-Myers Squibb Co.: Revenue by Geographical Segmentation 2013
  • Exhibit 26: GlaxoSmithKline: Business Segmentation 2013
  • Exhibit 27: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 28: GlaxoSmithKline: Sales by Geography 2013
  • Exhibit 29: GlaxoSmithKline: Pipeline Products 2013
  • Exhibit 30: Menarini: Key Pipeline Products
  • Exhibit 31: Sanofi SA: Business Segmentation
  • Exhibit 32: Sanofi SA: Revenue by Business Segmentation 2013
  • Exhibit 33: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
  • Exhibit 34: Sanofi SA: Sales Revenue by Geographical Segmentation 2013
Back to Top